Based on the Roivant Sciences Ltd stock forecast from 5 analysts, the average analyst target price for Roivant Sciences Ltd is USD 18.31 over the next 12 months. Roivant Sciences Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Roivant Sciences Ltd is Bullish , which is based on 8 positive signals and 2 negative signals. At the last closing, Roivant Sciences Ltd’s stock price was USD 11.64. Roivant Sciences Ltd’s stock price has changed by -1.02% over the past week, -1.69% over the past month and +25.16% over the last year.
No recent analyst target price found for Roivant Sciences Ltd
No recent average analyst rating found for Roivant Sciences Ltd
Company Overview Roivant Sciences Ltd
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom. Read Less
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on bi...Read More
Frequently Asked Questions About Roivant Sciences Ltd (ROIV) Stock
Based on ratings from 5 analysts Roivant Sciences Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 7 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ROIV's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ROIV is USD 18.31 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 12.5.
ROIV stock's Price/Earning ratio is 2.04.
Our analysis grades ROIV stock's Price / Earning ratio at D. This means that ROIV stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ROIV may be fairly valued for its sector
The last closing price of ROIV's stock was USD 11.64.
The most recent market capitalization for ROIV is USD 8.64B.
Based on targets from 5 analysts, the average taret price for ROIV is projected at USD 18.31 over the next 12 months.
This means that ROIV's stock price may go up by +57.32% over the next 12 months.
We can't find any ETFs which contains Roivant Sciences Ltd's stock.
As per our most recent records Roivant Sciences Ltd has 908 Employees.
Roivant Sciences Ltd's registered address is 50 Broadway, London, United Kingdom, SW1H 0DB.
You can get more information about it from Roivant Sciences Ltd's website at https://roivant.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Roivant Sciences Ltd (ROIV) Stock
Based on ratings from 5 analysts Roivant Sciences Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 7 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ROIV's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ROIV is USD 18.31 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 12.5.
ROIV stock's Price/Earning ratio is 2.04.
Our analysis grades ROIV stock's Price / Earning ratio at D. This means that ROIV stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ROIV may be fairly valued for its sector
The last closing price of ROIV's stock was USD 11.64.
The most recent market capitalization for ROIV is USD 8.64B.
Based on targets from 5 analysts, the average taret price for ROIV is projected at USD 18.31 over the next 12 months.
This means that ROIV's stock price may go up by +57.32% over the next 12 months.
We can't find any ETFs which contains Roivant Sciences Ltd's stock.
As per our most recent records Roivant Sciences Ltd has 908 Employees.
Roivant Sciences Ltd's registered address is 50 Broadway, London, United Kingdom, SW1H 0DB.
You can get more information about it from Roivant Sciences Ltd's website at https://roivant.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ROIV !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
